Invion Ltd
ASX:IVX

Watchlist Manager
Invion Ltd Logo
Invion Ltd
ASX:IVX
Watchlist
Price: 0.105 AUD -8.7% Market Closed
Market Cap: 8.1m AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one IVX stock under the Base Case scenario is 0.124 AUD. Compared to the current market price of 0.105 AUD, Invion Ltd is Undervalued by 16%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IVX Relative Value
Base Case
0.124 AUD
Undervaluation 16%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.5
P/S
P/S
Price to Sales
5.5
vs History
84
vs Industry
24
Median 3Y
9.4
Median 5Y
15.7
Industry
2.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-24
Median 5Y
-31.1
Industry
21.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-17.1
Median 5Y
-17.1
Industry
16.7
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-7.8
Industry
24
More Details
0.6
P/B
P/B
Price to Book Value
0.6
vs History
92
vs Industry
71
Median 3Y
2.2
Median 5Y
3.6
Industry
2.2
More Details
5
EV/S
EV/S
Enterprise Value to Sales
5
vs History
88
vs Industry
25
Median 3Y
8.4
Median 5Y
15.3
Industry
2.7
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-21.5
Median 5Y
-29.7
Industry
12.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-21.5
Median 5Y
-29.7
Industry
16.3
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-15.8
Median 5Y
-15.8
Industry
15.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-7.3
Median 5Y
-7.3
Industry
17.7
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
92
vs Industry
72
Median 3Y
2.4
Median 5Y
5.4
Industry
1.9
More Details

Multiples Across Competitors

IVX Competitors Multiples
Invion Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Invion Ltd
ASX:IVX
8.1m AUD 5.5 -1.2 -1.1 -1.1
US
Eli Lilly and Co
NYSE:LLY
751.6B USD 15.3 67.7 36.3 39.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
377.4B USD 4.2 17.3 12.6 16.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.6 12.9 14.8
CH
Roche Holding AG
SIX:ROG
204.3B CHF 3.4 24.7 9.3 10.9
CH
Novartis AG
SIX:NOVN
188.5B CHF 4.4 18.4 10.8 14.5
UK
AstraZeneca PLC
LSE:AZN
162B GBP 4 28.1 130.7 197.1
US
Merck & Co Inc
NYSE:MRK
209.7B USD 3.3 12 8.9 10.8
IE
Endo International PLC
LSE:0Y5F
184.8B USD 79.7 -63.2 294 737.3
US
Pfizer Inc
NYSE:PFE
145.8B USD 2.3 18.5 7.8 11
P/E Multiple
Earnings Growth PEG
AU
Invion Ltd
ASX:IVX
Average P/E: 25.7
Negative Multiple: -1.2 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
67.7
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.3
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.6
18%
1
CH
Roche Holding AG
SIX:ROG
24.7
32%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.1
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -63.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.5
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Invion Ltd
ASX:IVX
Average EV/EBITDA: 437
Negative Multiple: -1.1 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.3
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
13%
1
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.7
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.9
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
294
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Invion Ltd
ASX:IVX
Average EV/EBIT: 1 875.5
Negative Multiple: -1.1 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.7
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.6
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.8
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14.5
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.1
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.8
11%
1
IE
E
Endo International PLC
LSE:0Y5F
737.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
11
10%
1.1

See Also

Summary
IVX intrinsic value, competitors valuation, and company profile.
DCF Valuation
IVX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IVX stock valuation using valuation multiples.
Wall Street Estimates
IVX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IVX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 267,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.